About Concordia International Corp. (TSE:CXR)
Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on Assets-130.11%
Frequently Asked Questions for Concordia International Corp. (TSE:CXR)
What is Concordia International Corp.'s stock symbol?
Concordia International Corp. trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CXR."
How were Concordia International Corp.'s earnings last quarter?
Concordia International Corp. (TSE:CXR) issued its earnings results on Thursday, August, 13th. The company reported $1.04 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.06 by $0.02. The business earned $95.34 million during the quarter, compared to analyst estimates of $87.41 million. View Concordia International Corp.'s Earnings History.
When will Concordia International Corp. make its next earnings announcement?
Who are some of Concordia International Corp.'s key competitors?
Some companies that are related to Concordia International Corp. include Aegerion Pharmaceuticals (AEGR), Bioquell plc (BQE), Bellerophon Therapeutics (BLPH), OptiBiotix Health plc (OPTI), Electromed (ELMD), Proteostasis Therapeutics (PTI), Evoke Pharma (EVOK), Ohr Pharmaceuticals (OHRP), ContraVir Pharmaceuticals (CTRV), Auris Medical Holding AG (EARS), Advanced Oncotherapy PLC (AVO), CorMedix (CRMD), Avacta Group Plc (AVCT), Scancell Holdings Plc (SCLP), Pernix Therapeutics Holdings (PTX), ANGLE plc (AGL), Redx Pharma PLC (REDX) and Anthera Pharmaceuticals (ANTH).
Who are Concordia International Corp.'s key executives?
Concordia International Corp.'s management team includes the folowing people:
- Wayne Kreppner, President, Chief Operating Officer (Age 41)
- Allan Oberman, Chief Executive Officer, Director (Age 59)
- David J. Price, Chief Financial Officer
- Graeme Duncan, President - Company's International Segment
- Arijit Mookerjee, Managing Director, Chief Financial Officer - Operations
- Adeel Ahmad, Chief Financial Officer of AMCo
- Francesco Tallarico, Chief Legal Officer and Secretary
- Jordan M. Kupinsky J.D., Non-Executive Independent Chairman of the Board (Age 44)
- Douglas N. Deeth, Independent Director (Age 69)
- Rochelle Fuhrmann, Independent Director (Age 47)
How do I buy Concordia International Corp. stock?
Shares of Concordia International Corp. and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Concordia International Corp.'s stock price today?
One share of Concordia International Corp. stock can currently be purchased for approximately C$0.61.
How big of a company is Concordia International Corp.?
Concordia International Corp. has a market capitalization of C$31.18 million.
How can I contact Concordia International Corp.?
Concordia International Corp.'s mailing address is 277 Lakeshore Rd E Suite 302, OAKVILLE, ON L6J 1H9, Canada. The company can be reached via phone at +1-905-8425150.
MarketBeat Community Rating for Concordia International Corp. (CXR)MarketBeat's community ratings are surveys of what our community members think about Concordia International Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Concordia International Corp. (TSE:CXR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Sell (Score: 1.00)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Concordia International Corp. (TSE:CXR)
Analysts' Ratings History for Concordia International Corp. (TSE:CXR)
(Data available from 11/23/2015 forward)
|2/9/2017||TD Securities||Downgrade||Hold -> Reduce|
|12/8/2016||Royal Bank Of Canada||Downgrade||Sector Perform -> Underperform|
|11/7/2016||Bloom Burton||Downgrade||Hold -> Sell|
|8/15/2016||Goldman Sachs Group, Inc. (The)||Lower Price Target||C$34.00 -> C$17.00|
|8/15/2016||CIBC||Downgrade||Sector Perform -> Underperform|
|3/21/2016||Dundee Securities||Lower Price Target||C$62.00 -> C$60.00|
Earnings History and Estimates Chart for Concordia International Corp. (TSE:CXR)
Earnings History by Quarter for Concordia International Corp. (TSE CXR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/21/2018|| || || || || || || || |
|8/13/2015||Q2||C$1.06||C$1.04||C$87.41 million||C$95.34 million||View||Listen|
|8/13/2014||C$0.19||C($0.03)||C$24.42 million||C$28.49 million||View||N/A|
Earnings Estimates for Concordia International Corp. (TSE:CXR)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History by Quarter for Concordia International Corp. (TSE CXR)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Concordia International Corp. (TSE CXR)
Insider Trades by Quarter for Concordia International Corp. (TSE CXR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/25/2017||Erin Colleen O'neil||Director||Sell||191||C$1.74||C$332.34|
|5/16/2017||Graeme Neville Duncan||Director||Sell||7,065||C$1.91||C$13,494.15|
|2/1/2016||Mark Laurence Thompson||Director||Buy||60||C$28.77||C$1,726.20|
|11/17/2015||Wayne Walter Kreppner||Insider||Buy||3,000||C$43.67||C$131,010.00|
|11/16/2015||Mark Laurence Thompson||Director||Buy||23,150||C$43.36||C$1,003,702.98|
|7/17/2015||Wayne Walter Kreppner||Insider||Sell||4,800||C$103.00||C$494,400.00|
|6/26/2015||Robert Steven Altman||Insider||Sell||62,500||C$93.93||C$5,870,893.75|
|5/27/2015||Saldanha Adrian De||Insider||Buy||1,000||C$80.61||C$80,610.00|
|10/31/2014||James Christopher Reebals||Director||Sell||7,500||C$37.25||C$279,360.75|
|10/30/2014||James Christopher Reebals||Director||Sell||7,500||C$37.06||C$277,926.75|
|10/29/2014||James Christopher Reebals||Director||Sell||5,000||C$37.07||C$185,336.50|
Latest Headlines for Concordia International Corp. (TSE CXR)
Financials are not available for this stock.
Concordia International Corp. (TSE CXR) Chart for Thursday, November, 23, 2017